About: Iguratimod

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines. Adverse effects include elevated transaminases, nausea, vomiting, stomach pain; rashes, and itchiness. During discovery and development it was called T-614 and it is marketed under the names Careram and Kolbet.

Property	Value
dbo:abstract	Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines. Adverse effects include elevated transaminases, nausea, vomiting, stomach pain; rashes, and itchiness. It is a derivative of 7-methanesulfonylamino-6-phenoxychromones and is a chromone with two amide groups; it was first published in 2000. It was submitted for regulatory approval in Japan in 2003; the application was withdrawn in 2009, and it was resubmitted with additional data in 2011 and approved for marketing in Japan in 2012. Eisai and Toyama Chemical market it in Japan. Approval was obtained in China in 2011 by Simcere, independently of the Japanese originators. During discovery and development it was called T-614 and it is marketed under the names Careram and Kolbet. (en) イグラチモド (Iguratimod) は、関節リウマチ治療薬の一つである。日本において、富山化学により開発された。2012年6月厚生労働省より製造販売承認を受け、製品名をエーザイがケアラム、大正富山医薬品がコルベットとして販売している。 (ja)
dbo:alternativeName	Careram; Kolbet (en)
dbo:casNumber	123663-49-0
dbo:chEMBL	2107455
dbo:fdaUniiCode	4IHY34Y2NV
dbo:pubchem	124246
dbo:thumbnail	wiki-commons:Special:FilePath/Iguratimod.svg?width=300
dbo:wikiPageID	37652346 (xsd:integer)
dbo:wikiPageLength	4517 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	999527150 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Elevated_transaminases dbr:Anti-inflammatory dbr:Rheumatoid_arthritis dbr:Cytokine dbr:Chromone dbr:Eisai_(company) dbr:NF-κB dbc:Formamides dbr:Toyama_Chemical dbc:Chromones dbc:Anti-inflammatory_and_antirheumatic_products dbc:Sulfonamides dbr:Biological_target dbr:Methotrexate dbr:COX-2
dbp:atcPrefix	None (en)
dbp:c	17 (xsd:integer)
dbp:casNumber	123663 (xsd:integer)
dbp:chembl	2107455 (xsd:integer)
dbp:chemspiderid	110694 (xsd:integer)
dbp:h	14 (xsd:integer)
dbp:iupacName	N-methanesulfonamide (en)
dbp:n	2 (xsd:integer)
dbp:o	6 (xsd:integer)
dbp:pubchem	124246 (xsd:integer)
dbp:s	1 (xsd:integer)
dbp:smiles	O=SC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	ANMATWQYLIFGOK-UHFFFAOYSA-N (en)
dbp:synonyms	T-614 (en)
dbp:tradename	Careram; Kolbet (en)
dbp:unii	4 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Fdacite
dct:subject	dbc:Formamides dbc:Chromones dbc:Anti-inflammatory_and_antirheumatic_products dbc:Sulfonamides
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:WikicatSulfonamides yago:Abstraction100002137 yago:Agent114778436 yago:Antibacterial102716205 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Medicine103740161 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:Drug yago:Statement106722453 yago:Substance100020090 yago:SulfaDrug104352070
rdfs:comment	イグラチモド (Iguratimod) は、関節リウマチ治療薬の一つである。日本において、富山化学により開発された。2012年6月厚生労働省より製造販売承認を受け、製品名をエーザイがケアラム、大正富山医薬品がコルベットとして販売している。 (ja) Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines. Adverse effects include elevated transaminases, nausea, vomiting, stomach pain; rashes, and itchiness. During discovery and development it was called T-614 and it is marketed under the names Careram and Kolbet. (en)
rdfs:label	Iguratimod (en) イグラチモド (ja)
owl:sameAs	freebase:Iguratimod yago-res:Iguratimod wikidata:Iguratimod dbpedia-ja:Iguratimod dbpedia-sh:Iguratimod dbpedia-sr:Iguratimod https://global.dbpedia.org/id/MyEA
prov:wasDerivedFrom	wikipedia-en:Iguratimod?oldid=999527150&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Iguratimod.svg
foaf:isPrimaryTopicOf	wikipedia-en:Iguratimod
is dbo:wikiPageRedirects of	dbr:C17H14N2O6S
is dbo:wikiPageWikiLink of	dbr:Simcere_Pharmaceutical dbr:NF-κB dbr:C17H14N2O6S
is foaf:primaryTopic of	wikipedia-en:Iguratimod

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License